Zydus Cadila's Covid-19 therapy 'PegiHep' completes Phase II trial
- Based upon the results from its Phase 2 study, the drug firm now plans to conduct a phase 3 clinical trial in India, Zydus Cadila said in a regulatory filing
Pharmaceutical company Zydus Cadila on Thursday announced that it has "successfully completed" a phase 2 clinical trial in coronavirus patients with its biological therapy -- PegiHep -- and it will now start its phase 3 clinical trial.
Select your Category
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more